S&P 500   3,291.59 (-0.72%)
DOW   27,178.89 (-0.40%)
QQQ   269.26 (-1.18%)
AAPL   109.80 (-1.80%)
MSFT   204.69 (-1.32%)
FB   254.43 (-0.13%)
GOOGL   1,430.91 (-1.98%)
AMZN   3,061.29 (-2.16%)
NVDA   501.48 (-0.80%)
TSLA   393.16 (-7.32%)
BABA   275.31 (+0.01%)
CGC   14.68 (-8.48%)
GE   6.24 (-0.16%)
MU   50.75 (+2.11%)
AMD   76.54 (-1.49%)
T   28.26 (-0.88%)
F   6.78 (+0.00%)
ACB   5.43 (-25.82%)
GILD   63.83 (+0.68%)
NFLX   482.00 (-1.87%)
DIS   125.39 (-1.43%)
BAC   23.86 (-0.33%)
BA   155.46 (-0.85%)
S&P 500   3,291.59 (-0.72%)
DOW   27,178.89 (-0.40%)
QQQ   269.26 (-1.18%)
AAPL   109.80 (-1.80%)
MSFT   204.69 (-1.32%)
FB   254.43 (-0.13%)
GOOGL   1,430.91 (-1.98%)
AMZN   3,061.29 (-2.16%)
NVDA   501.48 (-0.80%)
TSLA   393.16 (-7.32%)
BABA   275.31 (+0.01%)
CGC   14.68 (-8.48%)
GE   6.24 (-0.16%)
MU   50.75 (+2.11%)
AMD   76.54 (-1.49%)
T   28.26 (-0.88%)
F   6.78 (+0.00%)
ACB   5.43 (-25.82%)
GILD   63.83 (+0.68%)
NFLX   482.00 (-1.87%)
DIS   125.39 (-1.43%)
BAC   23.86 (-0.33%)
BA   155.46 (-0.85%)
S&P 500   3,291.59 (-0.72%)
DOW   27,178.89 (-0.40%)
QQQ   269.26 (-1.18%)
AAPL   109.80 (-1.80%)
MSFT   204.69 (-1.32%)
FB   254.43 (-0.13%)
GOOGL   1,430.91 (-1.98%)
AMZN   3,061.29 (-2.16%)
NVDA   501.48 (-0.80%)
TSLA   393.16 (-7.32%)
BABA   275.31 (+0.01%)
CGC   14.68 (-8.48%)
GE   6.24 (-0.16%)
MU   50.75 (+2.11%)
AMD   76.54 (-1.49%)
T   28.26 (-0.88%)
F   6.78 (+0.00%)
ACB   5.43 (-25.82%)
GILD   63.83 (+0.68%)
NFLX   482.00 (-1.87%)
DIS   125.39 (-1.43%)
BAC   23.86 (-0.33%)
BA   155.46 (-0.85%)
S&P 500   3,291.59 (-0.72%)
DOW   27,178.89 (-0.40%)
QQQ   269.26 (-1.18%)
AAPL   109.80 (-1.80%)
MSFT   204.69 (-1.32%)
FB   254.43 (-0.13%)
GOOGL   1,430.91 (-1.98%)
AMZN   3,061.29 (-2.16%)
NVDA   501.48 (-0.80%)
TSLA   393.16 (-7.32%)
BABA   275.31 (+0.01%)
CGC   14.68 (-8.48%)
GE   6.24 (-0.16%)
MU   50.75 (+2.11%)
AMD   76.54 (-1.49%)
T   28.26 (-0.88%)
F   6.78 (+0.00%)
ACB   5.43 (-25.82%)
GILD   63.83 (+0.68%)
NFLX   482.00 (-1.87%)
DIS   125.39 (-1.43%)
BAC   23.86 (-0.33%)
BA   155.46 (-0.85%)
Log in
NYSE:BMY

Bristol-Myers Squibb Stock Forecast, Price & News

$59.37
+0.61 (+1.04 %)
(As of 09/23/2020 01:15 PM ET)
Add
Compare
Today's Range
$58.63
Now: $59.37▼
$59.49
50-Day Range
$57.77
MA: $61.01▼
$63.64
52-Week Range
$45.76
Now: $59.37▼
$68.34
Volume352,823 shs
Average Volume14.27 million shs
Market Capitalization$134.34 billion
P/E RatioN/A
Dividend Yield3.12%
Beta0.7
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, the company offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV) and Evotaz; Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics; Janssen Pharmaceuticals, Inc.; Biocartis Group NV.; and FameWave Ltd. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Read More
Bristol-Myers Squibb logo

Beat the Market (BTM) Rank™

Analyst Opinion: 2.4Community Rank: 2.6Dividend Strength: 2.5Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.82 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNYSE:BMY
Previous Symbol
CUSIP11012210
CIK14272
Webwww.bms.com
Phone212-546-4000

Debt

Debt-to-Equity Ratio0.85
Current Ratio1.47
Quick Ratio1.36

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E Ratio9.51
P/E Growth1.1

Sales & Book Value

Annual Sales$26.15 billion
Price / Sales5.14
Cash Flow$4.40 per share
Price / Cash Flow13.50
Book Value$23.20 per share
Price / Book2.56

Profitability

EPS (Most Recent Fiscal Year)$4.69
Net Income$3.44 billion
Net Margins-1.61%
Return on Equity28.47%
Return on Assets10.79%

Miscellaneous

Employees30,000
Outstanding Shares2,262,690,000
Market Cap$134.34 billion
Next Earnings Date11/5/2020 (Confirmed)
OptionableOptionable
$59.37
+0.61 (+1.04 %)
(As of 09/23/2020 01:15 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BMY News and Ratings via Email

Sign-up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions

How has Bristol-Myers Squibb's stock been impacted by Coronavirus?

Bristol-Myers Squibb's stock was trading at $56.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BMY stock has increased by 5.2% and is now trading at $59.46.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Bristol-Myers Squibb?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Bristol-Myers Squibb.

When is Bristol-Myers Squibb's next earnings date?

Bristol-Myers Squibb is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Bristol-Myers Squibb.

How can I listen to Bristol-Myers Squibb's earnings call?

Bristol-Myers Squibb will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Bristol-Myers Squibb's earnings last quarter?

Bristol-Myers Squibb Co (NYSE:BMY) announced its quarterly earnings results on Thursday, August, 6th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.48 by $0.15. The biopharmaceutical company earned $10.13 billion during the quarter, compared to analyst estimates of $10.04 billion. Bristol-Myers Squibb had a positive return on equity of 28.47% and a negative net margin of 1.61%. The business's quarterly revenue was up 61.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.18 EPS.
View Bristol-Myers Squibb's earnings history.

How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?

Bristol-Myers Squibb announced a quarterly dividend on Thursday, September 10th. Shareholders of record on Friday, October 2nd will be given a dividend of $0.45 per share on Monday, November 2nd. This represents a $1.80 annualized dividend and a yield of 3.03%. The ex-dividend date of this dividend is Thursday, October 1st.
View Bristol-Myers Squibb's dividend history.

What guidance has Bristol-Myers Squibb issued on next quarter's earnings?

Bristol-Myers Squibb updated its FY20 earnings guidance on Thursday, August, 6th. The company provided earnings per share guidance of $6.10-6.25 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.22. The company issued revenue guidance of $40.5-42.0 billion, compared to the consensus revenue estimate of $42.00 billion.

What price target have analysts set for BMY?

14 equities research analysts have issued 1-year price objectives for Bristol-Myers Squibb's stock. Their forecasts range from $50.00 to $88.00. On average, they expect Bristol-Myers Squibb's share price to reach $70.67 in the next year. This suggests a possible upside of 18.8% from the stock's current price.
View analysts' price targets for Bristol-Myers Squibb.

Who are some of Bristol-Myers Squibb's key competitors?

Some companies that are related to Bristol-Myers Squibb include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Zoetis (ZTS), Horizon Therapeutics (HZNP), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Mylan (MYL), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX).
View all competitors.

What other stocks do shareholders of Bristol-Myers Squibb own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bristol-Myers Squibb investors own include AbbVie (ABBV), AT&T (T), Pfizer (PFE), Verizon Communications (VZ), Intel (INTC), Johnson & Johnson (JNJ), NVIDIA (NVDA), CVS Health (CVS), Cisco Systems (CSCO) and Bank of America (BAC).

Who are Bristol-Myers Squibb's key executives?

Bristol-Myers Squibb's management team includes the following people:
  • Dr. Giovanni Caforio, Chairman & CEO (Age 54)
  • Mr. Charles A. Bancroft, Exec. VP of Global Bus. Operations & CFO (Age 59)
  • Dr. Thomas J. Lynch Jr., Exec. VP & Chief Scientific Officer (Age 58)
  • Ms. Sandra Leung Esq., Exec. VP & Gen. Counsel (Age 58)
  • Mr. Paul von Autenried, Sr. VP & Chief Information Officer (Age 57)

What is Bristol-Myers Squibb's stock symbol?

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

Who are Bristol-Myers Squibb's major shareholders?

Bristol-Myers Squibb's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.01%), Nordea Investment Management AB (0.87%), Charles Schwab Investment Management Inc. (0.49%), Independent Franchise Partners LLP (0.48%), Sumitomo Mitsui Trust Holdings Inc. (0.47%) and Swiss National Bank (0.40%). Company insiders that own Bristol-Myers Squibb stock include Adam Dubow, Dinesh C Paliwal, Giovanni Caforio, John E Elicker, Joseph Eid, Karen Murphy Santiago, Louis S Schmukler, Robert J Bertolini, Sandra Leung and Theodore R Samuels II.
View institutional ownership trends for Bristol-Myers Squibb.

Which major investors are selling Bristol-Myers Squibb stock?

BMY stock was sold by a variety of institutional investors in the last quarter, including Charles Schwab Investment Management Inc., Toronto Dominion Bank, First Trust Advisors LP, Railway Pension Investments Ltd, Sumitomo Mitsui Trust Holdings Inc., AQR Capital Management LLC, State of Tennessee Treasury Department, and Toronto Dominion Bank. Company insiders that have sold Bristol-Myers Squibb company stock in the last year include Adam Dubow, Giovanni Caforio, John E Elicker, Joseph Eid, Louis S Schmukler, and Sandra Leung.
View insider buying and selling activity for Bristol-Myers Squibb.

Which major investors are buying Bristol-Myers Squibb stock?

BMY stock was acquired by a variety of institutional investors in the last quarter, including Nordea Investment Management AB, Vanguard Group Inc., GQG Partners LLC, Two Sigma Advisers LP, Federated Hermes Inc., AJO LP, Independent Franchise Partners LLP, and Laidlaw Wealth Management LLC. Company insiders that have bought Bristol-Myers Squibb stock in the last two years include Dinesh C Paliwal, Robert J Bertolini, and Theodore R Samuels II.
View insider buying and selling activity for Bristol-Myers Squibb.

How do I buy shares of Bristol-Myers Squibb?

Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bristol-Myers Squibb's stock price today?

One share of BMY stock can currently be purchased for approximately $59.46.

How big of a company is Bristol-Myers Squibb?

Bristol-Myers Squibb has a market capitalization of $134.54 billion and generates $26.15 billion in revenue each year. The biopharmaceutical company earns $3.44 billion in net income (profit) each year or $4.69 on an earnings per share basis. Bristol-Myers Squibb employs 30,000 workers across the globe.

What is Bristol-Myers Squibb's official website?

The official website for Bristol-Myers Squibb is www.bms.com.

How can I contact Bristol-Myers Squibb?

Bristol-Myers Squibb's mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected]

This page was last updated on 9/23/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.